A routine lipid panel checks cholesterol and triglycerides, but usually not lipoprotein(a), a largely inherited particle that cardiology guidelines now say should be measured once in every adult's life.
What a standard cholesterol panel doesn't show you
Lipoprotein(a), usually shortened to Lp(a), is a particle that travels through your blood alongside LDL and HDL, the cholesterol types most people have at least heard of.
Cholesterol doesn't dissolve in blood on its own, so your body moves it around inside carrier particles called lipoproteins. LDL, often called "bad cholesterol," delivers cholesterol out to your cells and tissues; when more is circulating than your body needs, some of it works its way into artery walls over time and helps build the plaques behind heart attacks and strokes. HDL, the "good cholesterol," works in the other direction: it picks up spare cholesterol from your tissues and carries it back to the liver, where it's broken down and cleared out. Lp(a) shares LDL's basic build, with one addition: a protein called apolipoprotein(a) attached to it. That extra protein closely resembles plasminogen, the protein your body normally uses to help dissolve blood clots, so Lp(a) is thought to interfere with clot breakdown as well as contribute to plaque build-up, giving it two separate routes to cardiovascular risk, according to a 2022 review in Biomolecules.
A standard lipid panel checks total cholesterol, LDL and HDL, together with triglycerides. Lp(a) sits outside that list by default, so you can have a clean LDL, a healthy HDL and normal triglycerides, and still carry an elevated Lp(a) that never shows up unless someone orders it on its own.
HDL, LDL and Lp(a), in plain terms
Three related particles with different jobs, and only two of them on a standard panel.
Why Lp(a) is mostly a matter of genetics, not habits
Most blood lipids respond, at least partly, to what you eat, how much you move and how much weight you carry. Lp(a) is the exception. Around 90% of the difference between people's Lp(a) levels traces back to variation in a single gene, LPA, and once your level is established it tends to stay close to that point for the rest of your life, according to a 2019 review in the Journal of Clinical Medicine.
That's also why Lp(a) is handled differently from LDL in clinical guidelines. LDL gets checked repeatedly and managed over years. Lp(a), by contrast, is now something major cardiology bodies recommend measuring once in adulthood, mainly to catch the smaller group of people whose inherited level is very high, a recommendation made by both the 2019 ESC/EAS dyslipidaemia guidelines and the 2022 EAS consensus statement.
Diet, exercise and keeping a healthy weight are still good for your heart. They just don't change this particular number by much.
Why it matters, even though you can't change it
Elevated Lp(a) is now considered an independent, causal contributor to atherosclerotic cardiovascular disease and to narrowing of the aortic valve, alongside LDL rather than instead of it, according to the 2022 EAS consensus statement. The 2019 ESC/EAS dyslipidaemia guidelines define very high levels as above roughly 180 mg/dL (430 nmol/L), a threshold meant to flag inherited risk that would otherwise stay invisible on a routine panel.
In practice, Lp(a) is rarely measured. A 2024 German registry study found that fewer than 5% of patients referred for rehabilitation after a heart attack or an aortic valve procedure had ever had their Lp(a) checked at the referring hospital, despite guidelines recommending it.
In September 2026, the largest trial of a dedicated Lp(a)-lowering drug reported its first results: pelacarsen significantly lowered Lp(a), but didn't reduce heart attacks, strokes or cardiovascular deaths compared with placebo in the overall trial population, according to topline results Novartis announced. Full data are still to be published, and other Lp(a)-lowering drugs remain in earlier-stage trials. For now, there's no approved treatment that directly lowers Lp(a), which is exactly why testing is framed here as information for your risk picture, not as a first step toward a dedicated therapy.
| What guidelines say | Detail |
|---|---|
| How often | At least once in adulthood, since levels are set early and stay roughly stable |
| Risk-enhancing level | From around 50 mg/dL (125 nmol/L) |
| Very high, inherited level | Above around 180 mg/dL (430 nmol/L) |
Who guidelines point to first
Because one measurement usually covers a lifetime, there's little downside to checking it. Guidelines point first to:
- A family history of early heart attack or stroke, especially before age 55 in a parent or sibling.
- A heart event despite otherwise normal numbers, where LDL and the rest of the panel looked fine beforehand.
- Anyone building a fuller picture of cardiovascular risk, as a one-off addition to a wider check, not a repeat test.
Testing Lp(a) at Aeon
Because Lp(a) only needs measuring once, Aeon offers it as its own standalone add-on rather than folding it into any single panel. It still pairs thematically with cardiovascular testing, so you can add it alongside panels like Cardiovascular Health or Lipids, which cover a wider set of markers, including ApoB.
| Test | Switzerland (CHF) | Germany (EUR) |
|---|---|---|
| Lipoprotein(a), standalone add-on | 66 / 29 for members | 39 / 19 for members |
| Cardiovascular Health panel | 529 / 449 for members | 235 / 215 for members |
The short version
Conclusion
Lp(a) is one of the few numbers in a blood test that genuinely only needs collecting once. Finding out where you stand closes a real gap in the standard picture, without asking anything more of you afterwards.
Frequently asked questions
Is Lipoprotein(a) part of a standard cholesterol test?
No. A standard lipid panel covers total cholesterol, LDL, HDL and triglycerides. Lp(a) has to be requested as its own, separate test.
How often do I need to have it measured?
Generally once, in adulthood. Because your level is set early and stays fairly stable, guidelines treat one measurement as enough unless your own doctor has a specific reason to repeat it.
Is a high result dangerous on its own?
It's read in context, alongside LDL, ApoB and your family history, not on its own. A high number is one input into a wider cardiovascular risk picture, something to discuss with a doctor, not a diagnosis by itself.
Can I lower my Lp(a) through diet or exercise?
Not meaningfully. Lp(a) is mostly genetic and doesn't move much with lifestyle changes. That doesn't make diet, movement and weight management pointless: they still shape the rest of your cardiovascular risk, just not this particular number.
Is Lp(a) testing covered by insurance in Switzerland?
Usually not, outside a diagnosed condition. Like most preventive biomarker testing, it's typically a self-pay addition rather than something basic insurance covers automatically.
Sources
- Ugovšek S, Šebeštjen M. "Lipoprotein(a)—The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation." Biomolecules. 2022;12(1):26. Supports the structural link to plasminogen and the antifibrinolytic/prothrombotic mechanism alongside the atherogenic one.
- Ward NC, Kostner KM, Sullivan DR, Nestel P, Watts GF. "Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?" J Clin Med. 2019;8(12):2073. Supports the ~90%, LPA-gene figure.
- Mach F, Baigent C, Catapano AL, et al. "2019 ESC/EAS Guidelines for the management of dyslipidaemias." Eur Heart J. 2020;41(1):111-188. Supports the once-in-adulthood recommendation and the >180 mg/dL (430 nmol/L) very-high threshold.
- Kronenberg F, Mora S, Stroes ESG, et al. "Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement." Eur Heart J. 2022;43(39):3925-3946. Supports the causal/independent risk-factor statement and the ~50 mg/dL (125 nmol/L) risk-enhancing threshold.
- Altmann C, Burlacu NA, Preuss T, Hlousek A, Eddicks S. "Prevalence of elevated lipoprotein(a) in cardiac rehabilitation patients — results from a large-scale multicentre registry in Germany." Clin Res Cardiol. 2024. Supports the under-5%-tested figure in Germany.
- Novartis. "Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)." Press release, 4 September 2026. Topline results only; full peer-reviewed data not yet published at the time of writing. Supports the statement that pelacarsen did not reduce the composite cardiovascular endpoint versus placebo in the overall trial population.
